ACCELERATING DEVELOPMENT AND
INCREASING AWARENESS AND ACCESS
OF PATIENTS WITH CANCER
TO IMMUNOTHERAPY
T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.
CAR T-cell therapy
Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.
For additional information on CAR T-cell technology please contact UKW.
Leadership
Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany
Scientific Director Bioproduction and Bioprocessing at Servier, and EFPIA project leader for T2EVOLVE IMI Consortium,
Suresnes Cedex, France
Funding
This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programe and EFPIA. More information can be found at: https://www.imi.europa.eu/
